FEMY — FEMASYS INC

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1339005 ·
Last close
$0.41
Market Cap
$24.76M
52W High
$0.63
52W Low
$0.33
ADV30
1,262,253
Next earnings
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 424,889 266,283 -4,223,533 846,100 16,495,245 5,386,041 9,205,352
Dec 2025 813,387 510,262 -4,622,728 -3,950,305 20,724,177 9,266,353 14,854,875
Sep 2025 729,394 435,556 -3,653,768 -4,194,821 16,290,153 4,569,038 11,733,902
Jun 2025 409,268 251,097 -3,851,566 -4,585,922 13,780,409 3,218,067 12,272,974

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,690,565
Investing CF
$-630,098
Financing CF
$25,135,255
CapEx
$-630,098
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.73
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-145,826,144
Inventory
$5,740,249
Receivables
$616,600
ST Investments
EBIT TTM
$-16,735,471
Pretax Income TTM
$-18,626,590
Interest Exp TTM
$1,891,119
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,293,313
EBITDA
$-17,246,636
Free Cash Flow
$-11,906,741
Enterprise Value
$21,392,566
Total Cash
$9,266,353
Total Debt
$4,696,964
Shares Out
60,390,686
Trailing EPS
$-0.25
Book Value
$0.10
ROE
-455.8%
ROA
-66.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,293,313 -17,588,669 -18,627,887 20,724,177 14,854,875 -18,690,565
Dec 2024 1,629,108 -17,785,805 -18,816,628 12,445,002 10,140,580 -19,444,009
Dec 2023 1,071,970 -14,508,415 -14,247,124 27,755,825 9,403,236 -11,280,546
Dec 2022 1,206,218 -11,600,264 -11,394,170 16,895,570 1,653,051 -10,731,973

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.29

Peers — same industry

TickerNameMarket CapLastDaily %
HRGN Harvard Apparatus Regenerative Technology, Inc. $24.61M $1.40
PETV PetVivo Holdings, Inc. $25.52M $0.70
MODD Modular Medical, Inc. $26.51M $4.90
CTSO Cytosorbents Corp $29.05M $0.46
PLSM Pulsenmore Ltd. $29.46M $4.53

News headlines (Yahoo Finance, 1h cache)

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
2026-05-13 13:00 · Yahoo
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
2026-05-08 20:05 · Yahoo
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
2026-05-05 13:00 · Yahoo
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
2026-04-22 13:00 · Yahoo
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
2026-04-16 13:00 · Yahoo
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
2026-04-01 13:00 · Yahoo
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
2026-03-31 20:05 · Yahoo
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
2026-03-18 13:00 · Yahoo
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
2026-03-10 13:00 · Yahoo
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-27 22:26 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.